Cyteir Therapeutics
Rad51 Inhibition for AID+ Cancers

Cyteir Therapeutics is a Jackson Labs spinout and pharmaceutical company developing small molecules targeting RAD51, an essential protein in DNA repair, for oncology and autoimmune indications. Cyteir’s platform operates on the hypothesis that diseased cells have more DNA damage than healthy cells, so they rely more heavily on DNA repair for survival. The intention is to block the movement of RAD51 to and from areas of damage, reducing diseased cells’ ability to repair themselves therefore¬†bringing about cell death in an effect called ‘synthetic lethality.’¬†


University
Jackson Labs
Sector
Life Science
Status
Active
Initial Investment Stage
Early
View Website